2021 Revenues ($USD) : $3,350,857,712
2021 Revenues (foreign currencies) : ₹247,746,000,000
2021 R&D spend : $202,880,634.50
2021 Number of Employees : 21,000
Fiscal Year End : 3/31/2021
Leader : K. Nityananda Reddy, vice chair and managing director

Starting in the late 1980s with a focus on manufacturing semi-synthetic penicillin (SSP), Aurobindo eventually entered the high-margin specialty generic formulations segment. The company also is entering the biosimilars market with the acquisition of Veritaz’s formulations business. Aurobindo also has a large preexisting formulation business focused on international markets. The company exports to more than 155 countries and derives more than 90% of its revenues from international operations. Operating one of the largest R&D facilities in India, Aurobindo also has three R&D centers in the U.S. —BB